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The activation of glycolytic flux is a biochemical char-
acteristic of growing cells. Several reports have demon-
strated the role of fructose 2,6-bisphosphate in this
process. In this paper we show that the levels of
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
(6PF2K/Fru-2,6-P2ase) mRNA are modulated in response
to serum and growth factors and this effect is due to
regulation of its transcription rate. The modulation of
the expression of this enzyme by growth factors differs
according their mitogenic effect; both lysophosphatidic
acid and epidermal growth factor, when added alone,
increased themRNA levels, but endothelin had no effect.
Furthermore, cAMP, which acts as an antimitogenic sig-
nal in Rat-1 fibroblasts, produced a decrease in 6PF2K/
Fru-2,6-P2ase mRNA and inhibited the effects of lyso-
phosphatidic acid and epidermal growth factor on
6PF2K/Fru-2,6-P2ase expression. PD 098059, a specific
inhibitor of the activation of the mitogen-activated pro-
tein kinase, was able to prevent the effect of EGF on
6PF2K/Fru-2,6-P2ase gene expression. These results im-
ply that activation of mitogen-activated protein kinase
is required for the stimulation of the transcription of
6PF2K/Fru-2,6-P2ase by EGF.
Quiescent cells can be stimulated to recommence DNA syn-
thesis by distinct and interactive signal transduction path-
ways. These signaling pathways trigger a cascade of molecular
events required for progression of DNA replication (1, 2). One of
the essential processes for this progression is the activation of
the glycolytic flux (3, 4). It is known that glycolysis is stimu-
lated both when growth promoting agents are added to quies-
cent cells and in many types of transformed cells (5–7). The
major regulatory step in the glycolytic pathway is 6-phospho-
fructo-1-kinase activity. Activation of glycolysis involves the
increase of fructose 2,6-bisphosphate (Fru-2,6-P2)
1 levels, a
potent allosteric stimulator of 6-phosphofructo-1-kinase (re-
viewed in Refs. 8 and 9). Fru-2,6-P2 content is regulated by the
bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (6PF2K/Fru-2,6-P2ase; EC 2.7.1.105/3.1.3.46),
which catalyzes both its synthesis and its degradation (8, 9).
Different 6PF2K/Fru-2,6-P2ase isoenzymes have been de-
scribed depending on the tissues and cell specificity. In rat, the
liver, the muscle, and the F-type isoforms are encoded by the
same gene arising from distinct promoters (10, 11). These
isoenzymes differ with respect to their N-terminal sequence,
regulation by phosphorylation, and kinetic properties. It has
been shown that the F-type is the isoform expressed in several
proliferative tissues and in serum-stimulated Rat-1 fibroblasts
(10). Although extensive studies have been performed on the
regulation of liver and muscle isoforms, this is not the case of
F-type.
Different reports have demonstrated that Fru-2,6-P2 levels
increase after stimulation of fibroblasts with fetal bovine se-
rum, insulin, epidermal growth factor (EGF), or tumor pro-
moter phorbol esters (12–21). In some cases, the increase in
this metabolite has been correlated with an increase in the
Vmax of 6-phosphofructo-2-kinase activity (19–24). Although
this metabolic effect is clear, the mechanism by which it is
achieved is not known. Recently, a study of the regulation of
Fru-2,6-P2 metabolism through different signal transduction
pathways has been performed using murine Swiss 3T3 fibro-
blasts as a model (21). However, the attempts to measure
regulation of 6PF2K/Fru-2,6-P2ase mRNA levels and transcrip-
tion rate were not successful because the cDNA probes avail-
able did not recognize Swiss 3T3 6PF2K/Fru-2,6-P2ase mRNA.
The aim of this work is to study the signaling pathways that
control the transcription of the 6PF2K/Fru-2,6-P2ase gene dur-
ing cell proliferation. For this propose, we have investigated
the effect of EGF, lysophosphatidic acid (LPA), endothelin, and
cholera toxin (CTx) on 6PF2K/Fru-2,6-P2ase gene expression in
Rat-1 fibroblasts and the role of mitogen-activated kinase
(MAPK) in this regulation.
EXPERIMENTAL PROCEDURES
Chemicals—[a-32P]dCTP (3000 Ci/mmol), [a-32P]UTP (3000 Ci/mmol),
[6-3H]thymidine (5 Ci/mmol), ECL Western kit, and Hybond-N mem-
branes were from Amersham International (Amersham, Bucks., United
Kingdom (UK)). The random-primer DNA-labeling kit was from Boeh-
ringer Mannheim. Fetal calf serum, minimum essential medium, and
penicillin/streptomycin were from Bio-Whittaker. EGF, LPA, insulin,
and endothelin-1 were from Sigma. Anti-phosphotyrosine monoclonal
antibody PY20 was from Affiniti Research Products Ltd. (Nottingham,
UK), and anti-MAPK monoclonal antibody was from Zymed Laborato-
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ries, Inc. (San Francisco, CA). PD 098059 was a gift from Dr. A. Saltiel,
Parke-Davis Pharmaceutical Division (Detroit, MI). Other materials
and chemicals were of the highest quality available.
Cell Cultures—Rat-1 fibroblasts were routinely grown in minimum
essential medium (MEM) supplemented with 10% (v/v) fetal calf serum
(FCS), 100 units of penicillin/ml, and 100 mg of streptomycin/ml at 37 °C
in a 5% CO2 atmosphere. For experimental purposes, cells were sub-
cultured in six-well plates or 100-mm dishes and their quiescence was
induced by maintaining the cells in serum-free medium during 24 h.
After this, cells were stimulated with either FCS or different growth
factors.
Measurement of DNA Synthesis—Quiescent Rat-1 cells were acti-
vated with 10% FCS and different growth factors. At the indicated
times, cells were exposed to [6-3H]thymidine (0.5 mCi/ml) for the last 1 h
of stimulation. Trichloroacetic acid-precipitable material was dissolved
in 0.1 M NaOH and quantified by liquid scintillation counting.
Fructose 2,6-Bisphosphate Determination—To measure Fru-2,6-P2
levels, Rat-1 cells were homogenized in 0.1 M NaOH, heated at 80 °C for
15 min, and centrifuged at 12,000 3 g for 5 min. Fru-2,6-P2 was
determined in supernatants by its ability to activate pyrophosphate-de-
pendent 6-phosphofructo-1-kinase from potato tubers as described by
Van Schaftingen et al. (25).
Western Blot Analysis—Immunoblot analysis were performed essen-
tially as described by Burnette (26). For 6PF2K/Fru-2,6-P2ase, we used
a 1:1000 dilution of a polyclonal antibody raised against the rat liver
protein (27). Western blot analysis of MAPK phosphorylation was per-
formed as described previously (28) using anti-phosphotyrosine or anti-
MAPK monoclonal antibodies. Bound antibodies were detected by en-
hanced chemiluminescence method. The amount of protein was
determined by densitometric scanning of the autoradiograms.
RNA Isolation and Analysis—Total RNA was extracted from Rat-1
cells by the LiCl/urea method (29). Northern blot analyses were carried
out by standard procedures (30). To detect 6PF2K/Fru-2,6-P2ase
mRNA, a 1.4-kilobase EcoRI fragment from pPKB plasmid was used as
a probe (31). The integrity of the RNA was verified by observing the
rRNA bands in the ethidium bromide gel under UV irradiation. The
level of mRNA was evaluated by densitometric scanning of the autora-
diograms and corrected for the amount of 18 S rRNA using a ribosomic
cDNA probe (32).
Transfection and CAT Assays—Stable transfections were performed
by the CaPO4 method as described by Sambrook et al. (30). Rat-1 cells
were plated at 106 cells/100-mm culture dish 24 h before transfection.
The DNA precipitate (50 mg of the HindIII/BspmI 59 flanking region of
the F isoform of 6PF2K/Fru-2,6-P2ase cloned into pBLCAT3 plasmid as
described by Lange (11) and 5 mg of pSV2Neo) were left overnight. After
24 h, the cells were trypsinized and replated at 1:4 dilution. G418 (400
mg/ml) was added 24 h later. Transfections containing resistant colonies
were pooled for experimentation. CAT activity determinations were
carried out as described by Ausebel et al. (33).
Other Methods—Protein was determined as described by Bradford
(34) with bovine serum albumin as a standard. Statistical significance
of difference was assessed by Student’s unpaired t test.
RESULTS
Regulation of Fru-2,6-P2 Metabolism by Serum—Confluent
Rat-1 fibroblasts were made quiescent by maintaining them in
serum-free medium for 24 h and then shifted to medium sup-
plemented with 10% fetal-calf serum. After serum addition, the
cells were harvested and samples were taken to be analyzed at
different times. The data reported in Table I show that, after
being exposed to serum, an increase of the intracellular Fru-
2,6-P2 content was detected. During this process, the amount of
6PF2K/Fru-2,6-P2ase protein also increased. This was meas-
ured by immunobloting with an antibody obtained against the
liver 6PF2K/Fru-2,6-P2ase (Fig. 1). To determine whether the
abundance of 6PF2K/Fru-2,6-P2ase protein was correlated
with the amount of 6PF2K/Fru-2,6-P2ase mRNA, Northern blot
analysis was done using a 1.4-kilobase cDNA probe (31). As
shown in Fig. 2, there was a transient increase in the level of
6PF2K/Fru-2,6-P2ase mRNA with a maximum at 12–15 h (5-
fold increase over serum deprivation mRNA levels) and a grad-
ual decline to serum-free mRNA levels by 30 h. The analysis of
the incorporation of [6-3H]thymidine into DNA during the
course of this experiment revealed that the peak in mRNA
accumulation was coincident with the onset of DNA synthesis
(Fig. 2).
To determine whether the regulation of 6PF2K/Fru-2,6-
P2ase mRNA levels was due to a regulation of its transcription
rate, Rat-1 fibroblasts were stable transfected with a CAT
reporter gene under transcriptional control of a 1.7-kilobase
genomic DNA fragment that contain the F-type promoter (11).
In preliminary RNase protection experiments, we observed
that the F-type isoform is the only one expressed in these cells.
Quiescent transfected cells were stimulated with 10% of serum,
and CAT activity was measured at different times. As shown in
Fig. 3, up to 4-fold induction of CAT activity was found at 4 and
8 h after addition of serum. In contrast, CAT activity did not
change in cells incubated in the absence of serum during this
period.
Effect of Growth Factors on 6PF2K/Fru-2,6-P2ase mRNA
Levels—In order to study the signal transduction pathways
that control the expression of 6PF2K/Fru-2,6-P2ase in Rat-1
fibroblasts during proliferation, we determined the effect of
EGF, LPA, endothelin, and cholera toxin (CTx) on 6PF2K/Fru-
2,6-P2ase mRNA levels. As shown in Table II, EGF at 10 ng/ml
TABLE I
Effect of serum addition on fructose 2,6-bisphosphate levels
Quiescent Rat-1 fibroblasts were stimulated with 10% FCS (v/v). At
the indicated incubation time, extracts for Fru-2,6-P2 quantification
were obtained. Data are means 6 S.E. from three independent experi-
ments. Statistically significant differences with respect to control cells
are indicated: *, p , 0.05; **, p , 0.01.
Fru-2,6-P2 content
6 h 12 h 24 h
pmol/mg of protein
Control 97 6 13 119 6 17 81 6 7
1 FCS 154 6 17* 211 6 15** 233 6 16**
FIG. 1. Effect of fetal calf serum on the levels of 6PF2K/Fru-
2,6-P2ase protein. Quiescent Rat-1 fibroblasts were stimulated with
MEM supplemented with 10% FCS (v/v). At the indicated incubation
time, 100 mg of total protein was extracted from cultured cells in the
presence (f) or in the absence (M) of FCS and analyzed by Western blot
using a polyclonal antibody raised against purified adult liver 6PF2K/
Fru-2,6-P2ase. A representative Western blot obtained with prepara-
tions including FCS is shown. The intensity of the autoradiographic
signal was quantified and is presented with respect to time zero, which
was considered as 1 arbitrary unit.
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and LPA at 70 mM increased the levels of 6PF2K/Fru-2,6-P2ase
mRNA 4- and 7-fold, respectively. No significant change in
6PF2K/Fru-2,6-P2ase mRNA levels was detected after endothe-
lin addition. Furthermore, 12-O-tetradecanoylphorbol-13-ace-
tate (TPA), an activator of protein kinase C (PKC) also failed to
increase 6PF2K/Fru-2,6-P2ase mRNA. In contrast, CTx at 10
ng/ml decreased the 6PF2K/Fru-2,6-P2ase mRNA levels by ap-
proximately 50%. In agreement with the results from measure-
ment of mRNA levels, addition of EGF and LPA to quiescent
Rat-1 fibroblasts induced an increase in Fru-2,6-P2 levels. In
contrast, TPA or endothelin did not modify the concentration of
this metabolite (Table III).
Both EGF and LPA induce the activation of the mitogen-
activated protein kinases ERK1 and ERK2 (MAPKs) through
the Ras-Raf-MEK pathway (35, 36). In Rat-1 fibroblasts, cAMP
can inhibit the activation of MAPKs by inhibiting Raf activa-
tion (37). To examine the correlation between MAPK activation
and the increase in 6PF2K/Fru-2,6-P2ase mRNA found after
mitogenic responses, quiescent Rat-1 cells were preincubated
with CTx for 90 min before stimulation with EGF and the
6PF2K/Fru-2,6-P2ase mRNA levels were then measured. The
phosphorylation state of ERK2 is shown in Fig. 4. As we ex-
pected, a phosphotyrosine protein that comigrated with ERK2
was detected after EGF and serum addition, but it was almost
undetectable with TPA. Preincubation with CTx blocked the
effect of EGF on ERK2 phosphorylation (panel B). Under these
experimental conditions, EGF produced a 4-fold increase on the
levels of 6PF2K/Fru-2,6-P2ase mRNA and preincubation with
CTx completely inhibited this effect (panel C). The same results
were obtained with LPA (data not shown).
Recently, PD 098059 has been identified as a specific cell-
permeant inhibitor of MEK (38). To prove that MAPK activa-
tion is involved in mediating the effect of EGF on 6PF2K/Fru-
2,6-P2ase expression, we examined the effect of this compound
on 6PF2K/Fru-2,6-P2ase mRNA levels. As shown in Fig. 5, PD
098059 is able to prevent the increase on 6PF2K/Fru-2,6-P2ase
mRNA by EGF. The concentration of inhibitor required to
avoid this activation was similar to the one reported to inhibit
MAPK (38).
The ability of PD 098059 to inhibit the effect EGF on 6PF2K/
Fru-2,6-P2ase mRNA levels was correlated with its ability to
prevent the activation of 6PF2K/Fru-2,6-P2ase transcription.
Cells stably transfected with a CAT reporter gene under tran-
scriptional control of 1.7-kilobase F-type promoter, were incu-
bated at different concentrations of PD 098059 and CAT activ-
FIG. 2. Expression of 6PF2K/Fru-2,6-P2ase mRNA during the
cell cycle of Rat-1 fibroblasts. Quiescent Rat-1 fibroblasts were
stimulated with MEM supplemented with 10% FCS (v/v). At the indi-
cated incubation times, total RNA (20 mg/lane) was extracted from
cultured cells in the presence (f) or absence (M) of FCS and analyzed by
Northern blot. Upper, a representative Northern blot obtained with
preparations including FCS is shown. Lower, the intensity of the auto-
radiographic signal was quantified by densitometric scanning and cor-
rected for the amount of RNA obtained with the 18 S rRNA probe.
Values are expressed relative to the value of control cells, which was
considered as 1 arbitrary unit. Data are means 6 S.E. of three inde-
pendent experiments. To measure thymidine incorporation, at the in-
dicated incubation times, serum-stimulated cells were exposed to
[6-3H]thymidine (0.5 mCi) during the last 1 h of stimulation, and incor-
poration was assayed by the trichloroacetic acid standard procedure.
Each point (E) represents the mean 6 S.E. of three independent exper-
iments, each one performed by triplicate.
FIG. 3. Transcriptional activity of 6PF2K/Fru-2,6-P2ase gene
during the cell cycle of Rat-1 fibroblasts Rat-1 fibroblasts stably
transfected with a CAT reporter gene under control of F-type
promoter were stimulated with MEM supplemented with 10%
FCS (v/v). At the indicated incubation times, CAT activity was meas-
ured from cultured cells. The intensity of the autoradiographic signal
was quantified by densitometric scanning. Each point represents the
mean 6 S.E. of three independent experiments.
TABLE II
Effect of growth factors on 6PF2K/Fru-2,6-P2ase mRNA levels
Quiescent Rat-1 fibroblasts were treated with different growth fac-
tors for 15 h at the following concentrations: FCS, 10% (v/v); EGF (10
ng/ml), LPA (70 mM), TPA (100 ng/ml), endothelin (100 nM), and cholera
toxin (10 ng/ml). Total RNA (20 mg/lane) was extracted and processed by
Northern-blot. The intensity of the autoradiographic signal was quan-
tified by densitometric scanning and corrected for the amount of RNA
obtained with the 18 S rRNA probe. Values are expressed relative to the
value of untreated cells, which was considered as 1 arbitrary unit. Data
are means 6 S.E. from three to five independent experiments.
Relative amount of 6PF2K/Fru-2,6-P2ase mRNA
Arbitrary units
Control 1.0
1 FCS 6.2 6 0.1
1 EGF 3.8 6 0.3
1 LPA 7.1 6 0.8
1 TPA 1.5 6 0.1
1 ET-1 1.4 6 0.2
1 CTx 0.5 6 0.1
TABLE III
Effect of growth factors on fructose 2,6-bisphosphate levels
Quiescent Rat-1 fibroblasts were stimulated with EGF (10 ng/ml),
LPA (70 mM), TPA (100 ng/ml), and cholera toxin (10 ng/ml). At the
indicated incubation time, extracts for Fru-2,6-P2 quantification were
obtained. Data are means 6 S.E. from three independent experiments.
Statistically significant differences with respect to control cells are
indicated: *, p , 0.05.
Fructose 2,6-P2 content
pmol/mg of protein
Control 119 6 17
1 EGF 167 6 3*
1 LPA 188 6 17*
1 TPA 111 6 25
1 CTx 110 6 11
MAPK Regulates 6PF2K/Fru-2,6-P2ase Expression2848
ity was assayed 8 h after addition of EGF. As expected, PD
098059 suppressed the increase of CAT activity induced by
EGF and the activity remaining at basal levels at high concen-
tration of the inhibitor (Fig. 6).
DISCUSSION
Several reports have pointed out the essential role of Fru-
2,6-P2 in the activation of glycolytic flux in growing cells (3, 4).
The levels of this metabolite increase in different proliferative
states (12–24, 39), and this change has been correlated with an
increase in 6-phosphofructo-2-kinase activity (18–24) and re-
cently with an increase in mRNA levels (40, 41). However, the
mechanisms by which growth factors regulate 6PF2K/Fru-2,6-
P2ase are still unclear. The results presented here demonstrate
that MAPK is involved in the regulation of 6PF2K/Fru-2,6-
P2ase gene transcription in response to mitogenic signals.
The modulation of the expression of 6PF2K/Fru-2,6-P2ase by
growth factors is concomitant with their mitogenic response.
Serum, LPA, and EGF, complete mitogens for Rat-1 fibroblasts
(42), were able to increase the mRNA levels of 6PF2K/Fru-2,6-
P2ase and Fru-2,6-P2 content. In contrast, endothelin, which
has a low mitogenic activity (43), had no significant effect on
the expression of this enzyme. Indeed, cAMP produced a de-
crease in 6PF2K/Fru-2,6-P2ase mRNA levels and inhibited the
effect of LPA and EGF. In agreement with these results, Dar-
ville et al. (41) have demonstrated that cAMP was also able to
block the effect of serum on 6PF2K/Fru-2,6-P2ase transcrip-
tion. Previous studies reported a different effect of cAMP on
Fru-2,6-P2 levels in fibroblasts. In Swiss 3T3 (21) and human
fibroblasts (16), cAMP induces an increase in the concentration
of Fru-2,6-P2, while in chick-embryo fibroblast (19), the pres-
FIG. 4. Effect of cAMP onMAPK activation and 6PF2K/Fru-2,6-
P2ase mRNA levels. For MAPK determination, quiescent Rat-1 fibro-
blasts were subjected to treatment: FCS (10% v/v), EGF (10 ng/ml), TPA
(100 ng/ml) for 5 min. In the case of EGF 1 CTx, cells were preincu-
bated with CTx (10 ng/ml) for 90 min before EGF treatment. After the
treatment, protein extracts were obtained and processed by Western
blot and MAPK. Panel A, MAPK was detected by Western blotting
using an anti-MAPK monoclonal antibody. Panel B, activated MAPK
was detected using the PY20 anti-phosphotyrosine antibody. Panel C,
quiescent Rat-1 fibroblasts were treated with the different agonists for
15 h. Total RNA (20 mg/lane) were extracted and processed by Northern
blot. The intensity of the autoradiographic signal was quantified by
densitometric scanning and corrected for the amount of RNA obtained
with the 18 S rRNA probe. Values are expressed relative to the value of
untreated cells, which was considered as 1 arbitrary unit. Data are
means 6 S.E. from three to five independent experiments.
FIG. 5. Effect of MAPK inhibitor PD 098059 on 6PF2K/Fru-2,6-
P2ase mRNA levels. Quiescent Rat-1 fibroblasts were cultured for
15 h with EGF (10 ng/ml) with the indicated concentrations of PD
098059. Total RNA (20 mg/lane) was extracted from cultured cells and
analyzed by Northern blot. Upper, a representative Northern blot is
shown. Lower, the intensity of the autoradiographic signal was quan-
tified by densitometric scanning and corrected for the amount of RNA
obtained with the 18 S rRNA probe. Values are expressed relative to the
value of untreated cells, which was considered as 1 arbitrary unit. Data
are means 6 S.E. from three to five independent experiments.
FIG. 6. Effect of MAPK inhibitor PD 098059 on the stimulation
of 6PF2K/Fru-2,6-P2ase transcription by EGF. Rat-1 fibroblasts
stably transfected with a CAT reporter gene under control of F-type
promoter were incubated for 1 h in the absence or in the presence of the
indicated concentration of PD 098059, then stimulated for another 8 h
in the absence (basal) or in the presence of EGF (10 ng/ml). Upper, a
autoradiography of a thin-layer chromatography plate from a repre-
sentative CAT assay is shown. Lower, the intensity of the autoradio-
graphic signal was quantified by densitometric scanning. Values are
expressed relative to the value of untreated cells which was considered
as 1 arbitrary unit. Data are means 6 S.E. from three independent
experiments.
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ence of dibutyryl cAMP did not change the levels of this me-
tabolite. It is very likely that the discrepancy between these
results is due to the different mitogenic role of cAMP in these
cells; cAMP is a mitogenic signal in Swiss 3T3 cells (44), but it
is a strong antimitogen in Rat-1 fibroblasts (37).
With regard to the signaling pathways that control the tran-
scription of the 6PF2K/Fru-2,6-P2ase gene during cell prolifer-
ation, our results suggest that agents or growth factors (LPA,
EGF) that activate the Ras-Raf-MEK-ERK pathway also in-
crease the levels of 6PF2K/Fru-2,6-P2ase mRNA. In Rat-1 fi-
broblasts, EGF promotes the activation of ERK1 and ERK2
proteins through a Ras-dependent pathway without affecting
inositol phosphate levels (42, 45). In the same cells, LPA acti-
vates at least three independent signaling cascades by coupling
its receptor to Gi and Gq proteins: stimulation of phospho-
lipases C and D via a pertussis toxin-insensitive G protein (Gq),
inhibition of adenylate cyclase via a pertussis toxin-sensitive G
protein (Gia), and activation of Ras via a pertussis toxin-sen-
sitive Gi protein (Gbg) (46). The activation of the Ras cascade
by LPA produces the stimulation of MAPK (36). In Rat-1 fibro-
blasts, Ras is a point of convergence of EGF and LPA signaling
pathways in the activation of MAPK. It has been shown that
raising the cAMP levels in the cell induces the hyperphospho-
rylation of Raf-1 by PKA, reducing the binding affinity of Raf-1
to Ras and consequently inhibiting the Ras-Raf-MEK-ERK
pathway (47). Our results show that the inhibition of this
pathway by cAMP also leads to an inhibition of the stimulatory
effect of EGF and LPA on 6PF2K/Fru-2,6-P2ase expression.
The effect of cAMP on 6PF2K/Fru-2,6-P2ase expression is prob-
ably due to inhibition of MAPK activation. The implication of
MAPK cascade on the expression of this enzyme has been
suggested previously (41). However, definitive experiments
were necessary to support this tentative hypothesis. Our find-
ing that a specific inhibitor of MEK can prevent the effect of
EGF on 6PF2K/Fru-2,6-P2ase mRNA levels and on the tran-
scriptional levels provides further evidence to confirm the idea
that MAPK is involved in regulating 6PF2K/Fru-2,6-P2ase ex-
pression during proliferative processes.
Activation of PKC increases Fru-2,6-P2 levels in different
cells (16–24). Although there is no direct evidence, several
reports suggest that PKC may regulate 6PF2K/Fru-2,6-P2ase
gene expression. In chick embryo fibroblasts, incubation with
TPA produced an increase in 6PF2K/Fru-2,6-P2ase activity and
this effect was abolished in cells incubated with actinomycin D,
cycloheximide, or puromycin (19). In fetal hepatocytes (22) and
Swiss 3T3 cells (21), the rise in 6PF2K/Fru-2,6-P2ase activity
produced by phorbol esters was inhibited by cycloheximide,
suggesting that it is due to enhanced expression of the protein.
Our results demonstrate that, in Rat-1 fibroblasts, endothelin,
a strong stimulator of PKC, and TPA, had no detectable effect
on 6PF2K/Fru-2,6-P2ase mRNA levels and Fru-2,6-P2, suggest-
ing that activation of PKC pathway alone is not enough to
stimulate 6PF2K/Fru-2,6-P2ase expression in these cells. It has
been reported that, in Rat-1 fibroblasts, endothelin fails to
stimulate ERK phosphorylation, despite its potent coupling to
the phospholipase C-PKC second messenger cascade (36). The
different contribution of PKC to MAPK activation could explain
the fact that, in Swiss 3T3 cells, bombesin, another phospho-
lipase C-activating agonist, was able to increase 6PF2K/Fru-
2,6-P2ase activity (21). In these cells, bombesin stimulates
MAPK activity via a pathway that is almost entirely dependent
on PKC (48).
Sequence analysis of the F promoter of 6PF2K/Fru-2,6-P2ase
reveals the presence of several DNA-binding sites that could
directly or indirectly regulate the transcription of the 6PF2K/
Fru-2,6-P2ase gene by MAPK activation. A region containing
three binding motifs for transcription factors of the ets onco-
gene family has been found in the F promoter (10). The tran-
scriptional activity of various Ets-related transcription factors
is regulated by MAPK. Thus, c-Ets-2 is both transcriptionally
activated and phosphorylated by MAPK (49). Furthermore,
phosphorylation of the Ets-related transcription factor p62TCF/
Elk-1 by MAPK stimulates ternary complex formation at c-fos
promoter, thus activating the fos transcription and conse-
quently, the AP-1 DNA binding activity (50–52). Darville et al.
(53) reported an AP-1 DNA-binding site about 250 bp down-
stream of the F promoter, and several reports show that an
intronic AP-1 site could regulate gene expression (54–56). In-
deed, in the same 6PF2K/Fru-2,6-P2ase gene, a potent glu-
cocorticoid response element was identified in the first intron of
liver transcript (11).
Recently, an E2F binding site localized at the 59 end of the
first exon has been suggested to be involved in the serum
regulation of F promoter (41). E2F transcriptional activity is
blocked by its binding to hypophosphorylated retinoblastoma
protein (pRB). G1 cyclins, including cyclin D1, forms complexes
with cyclin-dependent kinases which can phosphorylate pRB,
causing to release E2F (57). Although there is no evidence,
MAPK pathway could regulate the dissociation of E2F from
retinoblastoma protein (pRB) leading to activation of E2F tar-
get genes. In this sense, EGF induction of cyclin D1 transcrip-
tion was antagonized by either dominant negative MAPK or
dominant negatives of Ets-2 activation, suggesting that MAPK
and Ets-2 function downstream of EGF in the context of cyclin
D1 induction (58). It would be very interesting to study
whether this putative MAPK-Ets-cyclin D1-pRB-E2F pathway
controls 6PF2K/Fru-2,6-P2ase expression.
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